BioCentury
ARTICLE | Clinical News

Aranesp darbepoetin alfa hematology data

May 4, 2009 7:00 AM UTC

A meta-analysis of 6 double-blind studies in 2,122 patients with non-myeloid tumors receiving chemotherapy showed that Aranesp increased the risk of thromboembolic events vs. placebo (8% vs. 5%), but ...